Empower Clinics: MediSure Submits Health Canada Application for its Rapid COVID-19 Antigen Tests
Dec 27, 2021 By MarketDepth
Empower Clinics Inc. (CSE: CBDT) (OTCQB: EPWCF) has announced that its subsidiary MediSure Canada has submitted an application to Health Canada for an Interim Order Approval to manufacture and sell MediSure Canada Lteral Flow Rapid COVID-19 Antigen Tests. “We acquired MediSure precisely to support their plans to diversify their medical device portfolio. This Health Canada submission demonstrates how these goals are being achieved.” said Steven McAuley, Chairman and CEO of Empower. “As a Canadian company, we’re proud to provide made-in-Canada testing solutions as we navigate another challenging winter. We’re working closely with Health Canada, so we can begin distribution as soon as possible.”
“I’m immensely proud of the MediSure team for its diligence and agility in the face of yet another COVID-19 wave. Utilizing MediSure’s two decades of healthcare manufacturing experience, we’re able to begin manufacturing COVID-19 tests with the utmost quality control in mind. When approved, these tests will expand the supply of COVID-19 tests at a time when Canadians need them the most.”
Mario Cortis, President of MediSure
Governments have pushed out rapid testing programs recently and are seeing large uptake and supply chain issues. MediSure prepares various activation steps to make its tests available as soon as it receives approval.
